Chronic inhibition of fatty acid oxidation: new model of diastolic dysfunction.
The proportion of cardiac energy derived from fatty acid oxidation decreases and that derived from glucose increases during ischemia. This biochemical profile of cardiac energy production is achieved in rats and mice without ischemia by pharmacological agents such as tetradecylglycidic acid. Chronically this leads to increased cardiac stiffness, and hypertrophy in the rodent models. Elements of human cardiac dysfunction are hypothesized to develop from and/or cause similar changes in substrate utilization for energy production. For some individuals treatment that would prevent or reverse these changes may be appropriate.
Bressler
R
R
Department of Internal Medicine, University of Arizona Health Sciences Center, Tucson.
Gay
R
R
Copeland
J G
JG
Bahl
J J
JJ
Bedotto
J
J
Goldman
S
S
D000818:Animals; D002331:Carnitine / Q000378:metabolism*; D002333:Carnitine Acyltransferases / Q000037:antagonists & inhibitors; D003327:Coronary Disease / Q000378:metabolism; D003971:Diastole; D004852:Epoxy Compounds / Q000494:pharmacology*; D004988:Ethers, Cyclic / Q000494:pharmacology*; D005227:Fatty Acids / Q000378:metabolism* / Q000494:pharmacology*; D005947:Glucose / Q000378:metabolism; D006321:Heart / Q000033:anatomy & histology; D006333:Heart Failure / Q000378:metabolism*; D016027:Heart Transplantation; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents; D051379:Mice; D009206:Myocardium / Q000378:metabolism*; D009929:Organ Size / Q000187:drug effects; D051381:Rats
D004852:Epoxy Compounds; D004988:Ethers, Cyclic; D005227:Fatty Acids; D007004:Hypoglycemic Agents; D002333:Carnitine Acyltransferases; D005947:Glucose; C021756:2-tetradecylglycidic acid; D002331:Carnitine